European Journal of Heart Failure

Papers
(The TQCC of European Journal of Heart Failure is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Epidemiology of heart failure875
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure720
Myocardial localization of coronavirus in COVID‐19 cardiogenic shock705
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Soci545
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio‐O338
Epidemiology, pathophysiology and contemporary management of cardiogenic shock – a position statement from the Heart Failure Association of the European Society of Cardiology223
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), th211
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial185
COVID‐19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease183
How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardio180
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and171
Heart failure in COVID‐19 patients: prevalence, incidence and prognostic implications166
Self‐care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology161
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology149
The impact of COVID‐19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic148
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial 146
Pulmonary artery pressure‐guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart F137
The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019115
Angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID‐19 infection in a multi‐site UK acute hospital trust113
Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: the FRAGILE‐HF cohort study110
Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity104
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study97
Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care97
Circulating cardiovascular microRNAs in critically ill COVID‐19 patients96
Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy95
Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology95
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID‐19. Results of the Cardio‐COVID‐Italy multicentre study93
Depression and heart failure: the lonely comorbidity92
Management of heart failure patients with COVID‐19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association 92
Primary results of long‐term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implan92
Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatme88
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial86
An expert consensus document on the management of cardiovascular manifestations of Fabry disease84
Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction81
Temporal trends in decompensated heart failure and outcomes during COVID‐19: a multisite report from heart failure referral centres in London81
Ultrasound imaging of congestion in heart failure: examinations beyond the heart81
Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper81
A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF80
Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF79
Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA‐EORP Heart Failure Long79
Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure78
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) 78
Light‐chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome77
The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM‐HF and ATMOSPHERE75
Association of COVID‐19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection75
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)74
Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient‐level database analysis73
Telemonitoring versus standard care in heart failure: a randomised multicentre trial73
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure73
Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction69
Trial characteristics associated with under‐enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review69
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta‐analysis69
Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium–glucose cotransporter 2 inhibitors69
Haemodynamic characteristics of COVID‐19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization68
Trends in cardiogenic shock complicating acute myocardial infarction68
Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction68
Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients – a prospective cohort study67
Cachexia, muscle wasting, and frailty in cardiovascular disease67
Regional adiposity and heart failure with preserved ejection fraction67
Characterization of NT‐proBNP in a large cohort of COVID‐19 patients66
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction65
Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis65
Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure65
Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta‐regression in the past four decades65
Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction64
Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC63
Heart failure management during the COVID‐19 outbreak in Italy: a telemedicine experience from a heart failure university tertiary referral centre61
Trends in prevalence of comorbidities in heart failure clinical trials61
Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction61
Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients61
Caring for people with heart failure and many other medical problems through and beyond the COVID‐19 pandemic: the advantages of universal access to home telemonitoring60
Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trials60
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics59
The impact of residual mitral regurgitation after MitraClip therapy in functional mitral regurgitation59
Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial58
Ejection fraction and mortality: a nationwide register‐based cohort study of 499 153 women and men56
Digital health care solution for proactive heart failure management with the Cordella Heart Failure System: results of the SIRONA first‐in‐human study56
The cancer patient and cardiology56
Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subje55
Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure55
Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology54
Effect of dapagliflozin on anaemia in DAPA‐HF53
Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy53
Sex‐related differences in contemporary biomarkers for heart failure: a review53
Clinical importance of urinary sodium excretion in acute heart failure51
Readmission and death in patients admitted with new‐onset versus worsening of chronic heart failure: insights from a nationwide cohort51
The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy50
Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart49
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review49
Contemporary survival trends and aetiological characterization in non‐ischaemic dilated cardiomyopathy48
Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO): impact of valve disease aetiology and r48
In‐hospital care in acute heart failure during the COVID‐19 pandemic: insights from the German‐wide Helios hospital network48
Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy48
Decreases in acute heart failure hospitalizations during COVID‐1947
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial47
Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high‐risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European So47
Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction45
Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo‐controlled, non‐inferiority ARIES HM3 trial45
OUTSTEP‐HF: randomised controlled trial comparing short‐term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fr44
A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction – insights from the ESC‐HFA EORP Heart Failure Long‐Term Regist44
One‐year results of the first‐in‐man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study44
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies44
High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality43
A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF‐HFpEF42
Virtual optimization of guideline‐directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT‐HF pilot study42
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials42
Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology41
The impact of palliative care on clinical and patient‐centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials40
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey40
Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology39
Recovery of cardiac function following COVID‐19 – ECHOVID‐19: a prospective longitudinal cohort study39
Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy – A clinical consensus statement of the Heart Failure Association and Eu38
Guideline‐directed medical therapy for heart failure does not exist: a non‐judgmental framework for describing the level of adherence to evidence‐based drug treatments for patients with a reduced ejec38
SARS‐CoV‐2‐related myocarditis‐like syndromes Shakespeare's question: what's in a name?38
Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry37
Urinary peptides in heart failure: a link to molecular pathophysiology37
Long‐term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system36
Effects of exergaming on exercise capacity in patients with heart failure: results of an international multicentre randomized controlled trial35
Telemonitoring in patients with chronic heart failure and moderate depressed symptoms: results of the Telemedical Interventional Monitoring in Heart Failure (TIM‐HF) study35
Cardiac, renal, and metabolic effects of sodium–glucose co‐transporter 2 inhibitors: a position paper from the European Society of Cardiology ad‐hoc task force on sodium–glucose co‐transporter 2 inhib35
Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations35
Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata34
Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the Eu34
Worsening renal function in acute heart failure in the context of diuretic response34
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI34
Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: first‐in‐human clinical trial34
Transcatheter tricuspid valve repair in the setting of heart failure with preserved or reduced left ventricular ejection fraction33
Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial33
The combination of carboxy‐terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic33
Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care33
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA‐HF trial32
Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry32
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial32
Serum potassium in the PARADIGM‐HF trial32
Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of 31
Gut dysbiosis and heart failure: navigating the universe within31
Use of biomarkers to diagnose and manage cardiac amyloidosis31
MiRNA‐181a is a novel regulator of aldosterone–mineralocorticoid receptor‐mediated cardiac remodelling31
Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC‐EORP Heart Failure Long‐Term Registry31
Cardiac iron concentration in relation to systemic iron status and disease severity in non‐ischaemic heart failure with reduced ejection fraction31
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index31
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced31
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction30
Pathogenesis and management of myocardial injury in coronavirus disease 201930
Epicardial fat in heart failure with reduced versus preserved ejection fraction30
Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of th30
The HFA‐PEFF and H2FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction30
Natural history and impact of treatment with tafamidis on major cardiovascular outcome‐free survival time in a cohort of patients with transthyretin amyloidosis30
Targeting pulmonary capillary permeability to reduce lung congestion in heart failure: a randomized, controlled pilot trial30
A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure30
Use of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry29
Ischaemic cardiomyopathy. Pathophysiological insights, diagnostic management and the roles of revascularisation and device treatment. Gaps and dilemmas in the era of advanced technology29
COVID‐19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology29
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF29
Long‐term survivors of early breast cancer treated with chemotherapy are characterized by a pro‐inflammatory biomarker profile compared to matched controls29
Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high‐risk acute heart failure patients29
Serum uric acid, influence of sacubitril–valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON‐HF29
Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry29
Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials29
The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease29
Challenges and future perspectives of transcatheter tricuspid valve interventions: adopt old strategies or adapt to new opportunities?29
Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF29
Myocardial work and vascular dysfunction are partially improved at 12 months after COVID‐19 infection28
Efficacy and safety of sodium–glucose co‐transporter 2 inhibition according to left ventricular ejection fraction in DAPA‐HF28
Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities28
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology28
Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map28
Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real‐world multicentre experience28
Nutritional status in tricuspid regurgitation: implications of transcatheter repair28
A network analysis to identify pathophysiological pathways distinguishing ischaemic from non‐ischaemic heart failure27
Impact of left ventricular ejection fraction on clinical outcomes after left main coronary artery revascularization: results from the randomized EXCEL trial27
Predictors of left ventricular remodelling in patients with dilated cardiomyopathy – a cardiovascular magnetic resonance study27
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart fai27
Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR<27
Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial26
Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction26
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial26
European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the 26
Excess out‐of‐hospital deaths during the COVID‐19 outbreak: evidence of pulmonary embolism as a main determinant26
Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis26
The burden of non‐cardiac comorbidities and association with clinical outcomes in an acute heart failure trial – insights from ASCEND‐HF26
Transfer of a human gene variant associated with exceptional longevity improves cardiac function in obese type 2 diabetic mice through induction of the SDF‐1/CXCR4 signalling pat25
Incidence and risk factors for pacemaker implantation in light‐chain and transthyretin cardiac amyloidosis25
How can sodium–glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron‐deficient? Implications for understanding iron homeostasis in heart failure25
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF25
Natriuresis‐guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium‐based treatment algoritHm in Acute Heart Failure (PUSH‐AHF) tri25
Frequency, trends and institutional variation in 30‐day all‐cause mortality and unplanned readmissions following hospitalisation for heart failure in Australia and New Zealand25
Prevention of heart failure events with sodium–glucose co‐transporter 2 inhibitors across a spectrum of cardio‐renal‐metabolic risk25
Head‐to‐head comparison of contemporary heart failure risk scores24
Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT24
Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials24
Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR‐Preserved trial24
Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause – the Cardiogenic Shock Score24
Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis24
Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction24
Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire24
Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology24
Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1‐year results from the CHOICE‐MI registry24
Diagnostic scores predict morbidity and mortality in patients hospitalized for heart failure with preserved ejection fraction24
Effects of hyperkalaemia and non‐adherence to renin–angiotensin–aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity‐matched study24
National trends in heart failure mortality in men and women, United Kingdom, 2000–201724
Effects of combined renin–angiotensin–aldosterone system inhibitor and beta‐blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT‐CHF and 24
Practical outpatient management of worsening chronic heart failure23
The significance of left ventricular ejection time in heart failure with reduced ejection fraction23
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA‐REG OUTCOME trial23
Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure23
Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double‐blind, randomized, placebo‐controll23
Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiolo23
Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE‐HF trial roll‐in cohort23
Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study23
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis23
Proteomics to improve phenotyping in obese patients with heart failure with preserved ejection fraction23
Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity22
Prognostic impact of the updated 2018 HFA‐ESC definition of advanced heart failure: results from the HELP‐HF registry22
Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia22
Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction22
Systemic embolism in amyloid transthyretin cardiomyopathy22
The Heart Failure Association Atlas: rationale, objectives, and methods22
Value of the HFA‐PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis22
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF22
Impact of left atrial diameter on outcome in patients undergoing edge‐to‐edge mitral valve repair: results from the German TRAnscatheter Mitral valve Interventions (TRAMI) regist21
In‐hospital initiation of quadruple medical therapy for heart failure: making the post‐discharge vulnerable phase far less vulnerable21
Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document21
Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Gro21
Long‐term survival and life expectancy following an acute heart failure hospitalization in Australia and New Zealand21
Genetic and phenotypic profiling of supranormal ejection fraction reveals decreased survival and underdiagnosed heart failure21
Pharmacotherapy for heart failure with reduced ejection fraction and health‐related quality of life: a systematic review and meta‐analysis21
Effects of an outpatient intervention comprising nurse‐led non‐invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (AMULET study): 21
Prognostic impacts of dynamic cardiac structural changes in heart failure patients with preserved left ventricular ejection fraction21
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial21
Prevalence, characteristics and outcomes of older patients with hereditary versus wild‐type transthyretin amyloid cardiomyopathy21
Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence21
Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea21
Sex and central obesity in heart failure with preserved ejection fraction21
A randomized clinical trial on the short‐term effects of 12‐week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results fr20
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial20
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial20
Viral presence‐guided immunomodulation in lymphocytic myocarditis: an update20
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial20
Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis20
Ventricular tachyarrhythmia detection by implantable loop recording in patients with heart failure and preserved ejection fraction: the VIP‐HF study20
Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX‐AHF‐2 trial20
Heart failure with preserved ejection fraction according to the HFA‐PEFF score in COVID‐19 patients: clinical correlates and echocardiographic findings20
Effect of patient‐centered transitional care services on patient‐reported outcomes in heart failure: sex‐specific analysis of the PACT‐HF randomized controlled trial20
Heart failure treatment up‐titration and outcome and age: an analysis of BIOSTAT‐CHF19
Peripheral and pulmonary effects of inorganic nitrite during exercise in heart failure with preserved ejection fraction19
One‐year mortality after implantable cardioverter‐defibrillator placement within the Veterans Affairs Health System19
Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF19
Sex‐based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan19
Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment19
0.044970035552979